Cited 0 times in
Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권혁문 | - |
dc.date.accessioned | 2022-12-22T01:33:08Z | - |
dc.date.available | 2022-12-22T01:33:08Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191254 | - |
dc.description.abstract | Background: This study evaluated the circadian efficacy of a telmisartan 40 mg/S-amlodipine 2.5 mg fixed-dose combination (Telmisartan40/S-Amlodipine2.5) compared to telmisartan 80 mg (Telmisartan80) in patients with essential hypertension who did not respond to 2-4 weeks' treatment with telmisartan 40 mg. Methods: Eligible patients with essential hypertension (clinic mean sitting systolic blood pressure [MSSBP] ≥140 mmHg, or ≥ 130 mmHg in those with diabetes mellitus or chronic kidney disease) were randomly assigned to Telmisartan40/S-Amlodipine2.5 or Telmisartan80 for 8 weeks. All patients underwent ambulatory BP monitoring (ABPM) at baseline and 8 weeks later. Primary endpoints were changes in mean 24-h SBP and DBP on 24-h ABPM from baseline after 8 weeks. Secondary endpoints were changes in daytime, nighttime, and morning SBP and DBP, and clinic MSSBP and MSDBP. Results: A total of 316 Korean patients were enrolled, 217 patients were randomized to treatment, and 192 patients completed the study. Compared to Telmisartan80, Telmisartan40/S-Amlodipine2.5 showed significantly better reductions in 24-h mean SBP and DBP after 8 weeks. Telmisartan40/S-Amlodipine2.5 also significantly reduced secondary endpoints compared to Telmisartan80. Among 15 adverse events (7 [Telmisartan40/S-Amlodipine2.5] and 8 [Telmisartan80]), there were five adverse drug reactions; 14 events were mild, and none were identified with significant between-group differences. Conclusions: Telmisartan40/S-Amlodipine2.5 was tolerable and more effective than Telmisartan80 in lowering 24-h mean ambulatory BP in patients with essential hypertension not responding adequately to Telmisartan40. Our findings support the fact that the combination of S-amlodipine with telmisartan is more appropriate than increasing the dose of telmisartan monotherapy. Trial registration: ClinicalTrials.gov , NCT02231788 . Registered 4 September 2014. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Biomed Central | - |
dc.relation.isPartOf | Clinical Hypertension | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Bong-Joon Kim | - |
dc.contributor.googleauthor | Kyoung-Im Cho | - |
dc.contributor.googleauthor | Hyuck Moon Kwon | - |
dc.contributor.googleauthor | Seung-Min Choi | - |
dc.contributor.googleauthor | Chang-Hwan Yoon | - |
dc.contributor.googleauthor | Sang Wook Lim | - |
dc.contributor.googleauthor | Seung-Jae Joo | - |
dc.contributor.googleauthor | Nam Ho Lee | - |
dc.contributor.googleauthor | Sang-Yup Lim | - |
dc.contributor.googleauthor | Seong-Hoon Lim | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.identifier.doi | 10.1186/s40885-021-00184-0 | - |
dc.contributor.localId | A00260 | - |
dc.relation.journalcode | J02982 | - |
dc.identifier.eissn | 2056-5909 | - |
dc.identifier.pmid | 35227313 | - |
dc.subject.keyword | Amlodipine | - |
dc.subject.keyword | Circadian rhythm | - |
dc.subject.keyword | Drug combinations | - |
dc.subject.keyword | Essential hypertension | - |
dc.subject.keyword | Telmisartan | - |
dc.contributor.alternativeName | Kwon, Hyuck Moon | - |
dc.contributor.affiliatedAuthor | 권혁문 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 7 | - |
dc.identifier.bibliographicCitation | Clinical Hypertension, Vol.28(1) : 7, 2022-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.